These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 27127303)

  • 41. BAFF, APRIL and their receptors: structure, function and signaling.
    Bossen C; Schneider P
    Semin Immunol; 2006 Oct; 18(5):263-75. PubMed ID: 16914324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
    Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
    J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma.
    Dalla Palma B; Marchica V; Catarozzo MT; Giuliani N; Accardi F
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32961764
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
    Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
    Salazar-Camarena DC; Ortiz-Lazareno PC; Cruz A; Oregon-Romero E; Machado-Contreras JR; Muñoz-Valle JF; Orozco-López M; Marín-Rosales M; Palafox-Sánchez CA
    Lupus; 2016 May; 25(6):582-92. PubMed ID: 26424128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide.
    Kikuchi J; Kuroda Y; Koyama D; Osada N; Izumi T; Yasui H; Kawase T; Ichinohe T; Furukawa Y
    Cancer Res; 2018 Apr; 78(7):1766-1778. PubMed ID: 29363546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells.
    Yang M; Hase H; Legarda-Addison D; Varughese L; Seed B; Ting AT
    J Immunol; 2005 Sep; 175(5):2814-24. PubMed ID: 16116167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis.
    Cao H; Zhu K; Qiu L; Li S; Niu H; Hao M; Yang S; Zhao Z; Lai Y; Anderson JL; Fan J; Im HJ; Chen D; Roodman GD; Xiao G
    J Biol Chem; 2013 Oct; 288(42):30399-30410. PubMed ID: 24005670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
    Sanchez E; Li M; Kitto A; Li J; Wang CS; Kirk DT; Yellin O; Nichols CM; Dreyer MP; Ahles CP; Robinson A; Madden E; Waterman GN; Swift RA; Bonavida B; Boccia R; Vescio RA; Crowley J; Chen H; Berenson JR
    Br J Haematol; 2012 Sep; 158(6):727-38. PubMed ID: 22804669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
    He B; Chadburn A; Jou E; Schattner EJ; Knowles DM; Cerutti A
    J Immunol; 2004 Mar; 172(5):3268-79. PubMed ID: 14978135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
    Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
    Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
    Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
    Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation.
    Kim J; Gross JA; Dillon SR; Min JK; Elkon KB
    Autoimmunity; 2011 Mar; 44(2):69-81. PubMed ID: 21250838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rheumatoid arthritis fibroblast-like synoviocytes express BCMA and are stimulated by APRIL.
    Nagatani K; Itoh K; Nakajima K; Kuroki H; Katsuragawa Y; Mochizuki M; Aotsuka S; Mimori A
    Arthritis Rheum; 2007 Nov; 56(11):3554-63. PubMed ID: 17968879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
    Samur MK; Fulciniti M; Aktas Samur A; Bazarbachi AH; Tai YT; Prabhala R; Alonso A; Sperling AS; Campbell T; Petrocca F; Hege K; Kaiser S; Loiseau HA; Anderson KC; Munshi NC
    Nat Commun; 2021 Feb; 12(1):868. PubMed ID: 33558511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide.
    Works M; Soni N; Hauskins C; Sierra C; Baturevych A; Jones JC; Curtis W; Carlson P; Johnstone TG; Kugler D; Hause RJ; Jiang Y; Wimberly L; Clouser CR; Jessup HK; Sather B; Salmon RA; Ports MO
    Mol Cancer Ther; 2019 Dec; 18(12):2246-2257. PubMed ID: 31395689
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Halting multiple myeloma with MALT1 inhibition: suppressing BCMA-induced NF-κB and inducing immunogenic cell death.
    Yao Y; Yuan M; Shi M; Li W; Sha Y; Zhang Y; Yuan C; Luo J; Li Z; Liao C; Xu K; Niu M
    Blood Adv; 2024 Aug; 8(15):4003-4016. PubMed ID: 38820414
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation.
    Bera TK
    Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33003418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.